Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
VELDHOVEN, the Netherlands - ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program.
| Date | Total repurchased shares | Weighted average price | Total repurchased value |
| 5-Mar-18 | - | - | - |
| 6-Mar-18 | - | - | - |
| 7-Mar-18 | 5,000 | 162.00 | 810,011.50 |
| 8-Mar-18 | 19,055 | 166.13 | 3,165,597.76 |
| 9-Mar-18 | 24,000 | 167.93 | 4,030,381.90 |
ASML's current share buyback program was announced on 17 January 2018, and details are available on our website at https://www.asml.com/investors/share-buyback/en/s25436
This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).
| Media Relations Contacts | Investor Relations Contacts |
| Monique Mols, phone +31 6 528 444 18 | Skip Miller, phone +1 480 235 0934 |
| Niclas Mika, phone +31 6 201 528 63 | Marcel Kemp, phone +31 40 268 6494 |
